Preliminary analysis of RTOG 9708: adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer

Greven, Kathryn M.; Winter, Kathryn; Underhill, K.; Fontenesci, Jim; Cooper, Jay; Burke, Thomas W.

doi:10.1016/j.ijrobp.2003.10.019

Cited by 62 publications

(27 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Doxorubicin, cisplatin and paclitaxel have all been shown to have activity as a single agent, with response rates of 20～35% (16～19). RTOG reported the preliminary analysis of postoperative RT combined with cisplatin/paclitaxel chemotherapy for the patients with high-risk endometrial cancer (20). 66% of the eligible patients had stage lll disease.…”

Section: Discussionmentioning

confidence: 99%

Patterns of Failure after Postoperative Radiation Therapy for Endometrial Carcinoma

Kim

Lee

et al. 2006

Cancer Res Treat

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Patterns of Failure after Postoperative Radiation Therapy for Endometrial Carcinoma

Kim

Lee

et al. 2006

Cancer Res Treat

View full text Add to dashboard Cite

“…Although the feasibility and tolerability of using combined modality for patients with HREC in the postoperative setting have been demonstrated in the Radiation Therapy Oncology Group (RTOG) 9708 study, many physicians are still hesitant to adopt this concurrent regimen because of concerns of toxicity. [20] Another method of administering adjuvant chemoradiotherapy is the sequential scheme. Sequential schedules include providing radiotherapy after the completion of six cycles of chemotherapy or a "sandwich" approach where radiotherapy is interposed between split intervals of chemotherapy.…”

Section: Timing Of Adjuvant Radiotherapy In High-risk Endometrial Cancermentioning

confidence: 99%

“…The feasibility of using concurrent chemoradiation followed by chemotherapy was tested by the RTOG 9708 study. [20] The RTOG 9708 study included patients with grade 2 or 3 endometrial adenocarcinoma with > 50% myometrial invasion, stromal invasion of the cervix, or pelvic-confined extrauterine disease. The disease was stage III, II, and I in 66%, 16%, and 18% patients, respectively.…”

Section: Timing Of Adjuvant Radiotherapy In High-risk Endometrial Cancermentioning

confidence: 99%

Role and Timing of Radiotherapy in High-Risk Endometrial Cancer

Yavaş¹

2017

TJ Oncol

View full text Add to dashboard Cite

SUMMARYEndometrial cancer is the most common gynecological tumor in developed countries, and its incidence is increasing because of an increased prevalence of obesity and an aging population. Although most patients present with early-stage low-risk disease, a rise in the incidence is attributed to an increasing number of high-risk cases at the time of diagnosis. Despite optimal surgical treatment, the prognosis of high-risk endometrial cancer (HREC) is poor because of increased risk of local and distant recurrences and therefore, adjuvant treatment should be considered. Although the definition of high-risk patients varies between cooperative groups, the recent endometrial consensus conference defined high-risk patients as follows: (1) stage I endometrioid, grade 3, ≥50% myometrial invasion; (2) stage II disease; (3) stage III endometrioid, no residual disease; and (4) non-endometrioid histology. The optimal adjuvant treatment is controversial; however, multimodality treatment is recommended. External radiotherapy seems to be reasonable in HREC and is indicated to improve pelvic relapses. The use of adjuvant chemotherapy is also reasonable for preventing or delaying distant metastases. There is limited evidence for the benefit of vaginal cuff brachytherapy after external radiotherapy. Optimal sequence of radiation and chemotherapy is not well defined; however, concurrent chemoradiotherapy plus adjuvant chemotherapy, "sandwich" approach, and providing radiotherapy after the completion of chemotherapy may be reasonable. The role of adjuvant radiotherapy with systemic therapy for treating HREC remains an area of active investigation. Adjuvant treatment of HREC is evolving, and patients should be individually treated with respect to the stage, histology, and prognostic factors.

show abstract

“…Clearly there is a need for both local and systemic control in advanced staged endometrial cancer. Multiple different chemotherapy agents have been combined with both volume-directed and whole abdominal chemotherapy with acceptable toxicity and response rates (Table 2) [33][34][35][36][37]. All these studies, unfortunately, are limited by their small size.…”

Section: Chemotherapymentioning

confidence: 99%

Treatment for Advanced and Recurrent Endometrial Carcinoma: Combined Modalities

Rauh‐Hain

Carmen

2010

The Oncologist

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Discuss the role of radiation therapy for advanced stage endometrial cancer in order to differentiate between patients who should receive only radiation therapy and patients requiring surgery and/or chemotherapy in addition to radiation.2. Evaluate the role of surgery for stage IV and recurrent endometrial cancer in order to select patients most likely to benefit from cytoreductive surgery.3. Evaluate the role of chemotherapy, particularly in conjunction with radiotherapy, in advanced stage endometrial carcinoma and select appropriate candidates for multimodality therapy.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME ABSTRACTWomen with recurrent or advanced endometrial cancer constitute a heterogeneous group of patients. Depending on previous treatment, women with recurrent endometrial cancer may be appropriate candidates for surgery, radiation therapy, hormonal therapy, or chemotherapy. Women with advanced stage disease at presentation may also be appropriate candidates for systemic and local therapies. We review the treatment options available to treat recurrent and locally advanced endometrial cancer. Treatment choice depends largely on the localization of disease, the patient's performance status and previ-

show abstract

Preliminary analysis of RTOG 9708: adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer

Cited by 62 publications

References 25 publications

Patterns of Failure after Postoperative Radiation Therapy for Endometrial Carcinoma

Patterns of Failure after Postoperative Radiation Therapy for Endometrial Carcinoma

Role and Timing of Radiotherapy in High-Risk Endometrial Cancer

Treatment for Advanced and Recurrent Endometrial Carcinoma: Combined Modalities

Contact Info

Product

Resources

About